Mapping Global Interest in Semaglutide: How Social Media Drove a Weight Loss Drug Frenzy
Google Trends analysis across 27 countries showed semaglutide search interest surging from 2022, driven by weight loss interest rather than diabetes needs.
Quick Facts
What This Study Found
Semaglutide search interest increased dramatically from 2022 onward across most of the 27 countries studied. The US and Canada had the largest and most sustained interest.
Natural language processing of search queries revealed that weight loss was the dominant theme in most countries. A diabetes theme was generally absent or weak, confirming that public interest is driven by weight loss rather than the drug's original purpose.
Media coverage partially explained search interest (Granger causality analysis), with the UK and Germany showing strong relationships between news reports and subsequent search spikes. A single Dr. Oz TV episode coincided with search peaks across multiple countries. Some countries showed concerning themes: Australia, Chile, South Africa, and the UK had searches for buying Ozempic from specific retailers, and Germany had searches for obtaining it without a prescription.
Key Numbers
- 27 countries included
- Search interest surged from 2022 onward
- US and Canada: largest sustained interest
- Weight loss: dominant theme in most countries
- Diabetes theme: absent or weak in most countries
- Up to 4 significant within-country changepoints identified
- Dr. Oz TV episode: coincided with multi-country search peaks
How They Did This
Researchers used Google Trends Extended for Health (GTEH) with multiple sampling to retrieve regional online interest from all countries. They included 27 countries with sufficient search volume. Granger causality analysis tested whether media coverage predicted search interest. Joinpoint regression identified trend changepoints. Natural language processing identified themes in top search queries.
Why This Research Matters
The global surge in semaglutide interest for weight loss, driven by social media and mainstream media, created supply shortages that affected diabetes patients. Understanding the drivers of this interest can help regulators and healthcare systems prepare for similar surges with future drugs. The finding that weight loss dominates over diabetes searches confirms the off-label demand is consumer-driven.
The Bigger Picture
The social media-driven demand for semaglutide as a weight loss drug created worldwide supply shortages that affected diabetes patients. Understanding the information landscape helps regulators and healthcare systems respond.
What This Study Doesn't Tell Us
Google search data is a proxy for interest, not actual drug use or prescribing patterns. Countries with low internet penetration are underrepresented. The GTEH tool provides relative interest, not absolute search volumes. The study period ended in August 2023 and may not capture more recent trends. Social media data was not directly analyzed.
Questions This Raises
- ?Did social media promotion contribute to inappropriate prescribing?
- ?How can health systems balance weight loss demand with diabetes patient needs?
Trust & Context
- Key Stat:
- Weight loss dominant theme Across most of the 27 countries studied, weight loss was the primary search motivation for semaglutide, not diabetes treatment
- Evidence Grade:
- Rated moderate: well-designed infodemiological study using validated Google Trends methodology, but search data is a proxy for interest, not actual prescribing.
- Study Age:
- Published in 2024 analyzing data from 2021–2023. The demand landscape has continued evolving since the study period.
- Original Title:
- Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface.
- Published In:
- BMC global and public health, 2(1), 63 (2024)
- Database ID:
- RPEP-09127
Evidence Hierarchy
Frequently Asked Questions
Why did semaglutide become so popular?
Celebrity endorsements and social media promotion drove intense public interest in semaglutide for weight loss starting in 2022, far exceeding diabetes-related demand.
Did social media cause the Ozempic shortage?
This study shows weight loss interest (driven by social media) dominated searches, suggesting demand-side pressure contributed to supply shortages affecting diabetes patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09127APA
Raubenheimer, Jacques Eugene; Myburgh, Pieter Hermanus; Bhagavathula, Akshaya Srikanth. (2024). Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface.. BMC global and public health, 2(1), 63. https://doi.org/10.1186/s44263-024-00095-w
MLA
Raubenheimer, Jacques Eugene, et al. "Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface.." BMC global and public health, 2024. https://doi.org/10.1186/s44263-024-00095-w
RethinkPeptides
RethinkPeptides Research Database. "Sweetening the deal: an infodemiological study of worldwide ..." RPEP-09127. Retrieved from https://rethinkpeptides.com/research/raubenheimer-2024-sweetening-the-deal-an
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.